Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
about
Multivalent fusion protein vaccine for lymphatic filariasisLatest developments and future directions in dengue vaccinesDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesAn adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypesIdentification of Continuous Human B-Cell Epitopes in the Envelope Glycoprotein of Dengue Virus Type 3 (DENV-3)A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinConstruction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Alternative dosage schedules with HPV virus-like particle vaccines.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Broadening the heterologous cross-neutralizing antibody inducing ability of porcine reproductive and respiratory syndrome virus by breeding the GP4 or M genes.Next-generation dengue vaccines: novel strategies currently under development.The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in MiceCharacterization of conformation-dependent prion protein epitopes.Attenuation of porcine reproductive and respiratory syndrome virus by molecular breeding of virus envelope genes from genetically divergent strains.Domain III of the envelope protein as a dengue vaccine target.Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children.Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine developmentEDIII-DENV3 nanospheres drive immature dendritic cells into a mature phenotype in an in vitro model.Using the Theory of Planned Behavior to predict HPV vaccination intentions of college men.The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions.Dengue virus type-3 envelope protein domain III; expression and immunogenicity.Differences in HPV Immunization Levels Among Young Adults in Various Regions of the United States.
P2860
Q24630552-52066F36-AFD7-40AF-AF17-5903F20A7047Q27023422-80E4F6BA-4AE2-4E33-9F5A-598C99BD91F3Q27304342-AC579D33-83B8-407A-BE3D-A31870050373Q27478104-37BDD7A7-3654-40CF-A9A8-F4783151B846Q27489953-F388DD80-D9D3-4C48-B975-57784B1A4D23Q28743092-9FDD26E0-4201-4514-A862-0DC84F85A221Q30375514-84B89BC3-74EC-4C77-8B59-05972C4AAAFBQ33699057-949A7DAE-FE6F-4158-A1B2-13B3164280A1Q34102466-B7AD1A3A-4B2A-4436-88BE-3023BE366693Q34202440-A35A0D84-3838-4B4A-9FC0-AC16CED38B3EQ34795790-94A888A9-5385-4F69-B14B-9FB3B70CF31DQ35491639-C536CFC1-F175-49C4-9608-725C756CAC60Q35880666-EDFC65BC-6166-4EB9-907B-2B16A819BA96Q36347803-D926D0E0-2435-475F-BFA2-B123C7EBC845Q36506784-D58EAEAA-A93B-42E5-A765-8683A9497003Q37682895-1DF23284-4B7F-4D55-AF35-AED41D0AD22AQ37770376-1CAA885B-8127-4888-8B3A-F92CAC53F548Q38499117-338799BB-2A3B-41EB-A28E-CAD1B8273096Q38730891-9167F9C2-53EF-4D41-AC42-FDF76EA715D8Q39037723-C9808BA0-6376-4872-83B2-625D33DFF928Q39904593-591C350E-95DB-4B12-957F-2382285EAAF9Q40168970-D2928E02-338B-4CF5-8EC0-5A1D5424B387Q41453056-CA6F8334-2A07-4291-956A-AADB49AA9648
P2860
Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@ast
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@en
type
label
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@ast
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@en
prefLabel
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@ast
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@en
P2093
P1433
P1476
Tetravalent neutralizing antib ...... meric dengue envelope antigen.
@en
P2093
Alice Brinkman
Andrey Semyonov
Craig Skinner
Juha Punnonen
Kanakatte Raviprakash
Kevin Porter
Lori Diehl
Richard Lyons
Shumin Yang
P304
P356
10.1016/J.VACCINE.2005.07.100
P407
P577
2005-08-10T00:00:00Z